• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by I-MAB (Amendment)

    2/9/24 4:01:20 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMAB alert in real time by email
    SC 13G/A 1 tm245056d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*

     

    I-MAB

    (Name of Issuer)

     

    Ordinary shares, par value of $0.0001 per share
    (Title of Class of Securities)

     

    44975P 103**
    (CUSIP Number)

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    ¨Rule 13d-1(c)

     

    xRule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    **There is no CUSIP number assigned to the ordinary shares of the Issuer. CUSIP number 44975P 103 has been assigned to the American Depositary Shares ("ADSs") of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "IMAB." Each 10 ADSs represents 23 ordinary shares.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1

    NAMES OF REPORTING PERSONS

     

    Jingwu Zhang Zang

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)          ¨

    (b)          ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF SHARES
    BENEFICIALLY OWNED BY
    EACH REPORTING PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    10,454,937*

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    10,454,937*

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    10,454,937

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.60%**

    12

    TYPE OF REPORTING PERSON

     

    IN

     

    *Represents (i) 2,072,899 ordinary shares directly held by Mabcore Limited, a British Virgin Islands company, (ii) 273,256 ordinary shares held by Dr. Zang through The 2019 Hasselt Revocable Trust, (iii) 5,962,625 ordinary shares, including 114,890 ordinary shares in the form of ADSs, held by Dr. Zang through The Doctor Zang 2020 Dynasty Trust, and (iv) 1,140,241 ordinary shares in the form of ADSs and 1,005,916 ordinary shares issuable upon exercise of options exercisable within 60 days after December 31, 2023 held by Dr. Zang. The 2019 Hasselt Revocable Trust was established under the laws of the State California and is co-managed by Dr. Zang and Ms. Zang (Dr. Zang's spouse), each as a settlor and a trustee. The Doctor Zang 2020 Dynasty Trust was established under the laws of the State of California and is co-managed by Dr. Zang, as the settlor and the investment trustee, and by Ms. Zang, as the trustee.

     

    **Based on 185,613,662 ordinary shares outstanding as of December 31, 2023 (excluding 660,200 ordinary shares issued to the depositary bank of I-Mab for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of I-Mab and 7,799,867 treasury shares in the form of ADSs that the Issuer repurchased under its share repurchase program).

     

     

     

     

    1

    NAMES OF REPORTING PERSONS

     

    Mabcore Limited*

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)          ¨

    (b)          ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    British Virgin Islands

    NUMBER OF SHARES
    BENEFICIALLY OWNED BY
    EACH REPORTING PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    2,072,899

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    2,072,899

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,072,899

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    1.12%**

    12

    TYPE OF REPORTING PERSON

     

    CO

     

    *Dr. Zang, through himself and The Jingwu Zhang Zang 2018 Irrevocable Family Trust, owns a 55.6% equity interest in Mabcore Limited. Three other individuals own the remaining equity interest in Mabcore Limited. Dr. Zang is the sole director of Mabcore Limited. The Jingwu Zhang Zang 2018 Irrevocable Family Trust was established under the laws of New York and is co-managed by Ms. Zang, as the trustee, and by Dr. Zang, as the settlor. Pursuant to the currently effective memorandum and articles of association of Mabcore Limited, Dr. Zang, as the sole director, has the power to direct the actions of Mabcore Limited, including the voting and disposal of Mabcore Limited's shares in I-Mab. Accordingly, Dr. Zang is deemed to indirectly own all of the 2,072,899 ordinary shares held by Mabcore Limited, while three other individuals are only entitled to their respective pro-rata economic interest in Mabcore Limited.

     

    **Based on 185,613,662 ordinary shares outstanding as of December 31, 2023 (excluding 660,200 ordinary shares issued to the depositary bank of I-Mab for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of I-Mab and 7,799,867 treasury shares in the form of ADSs that the Issuer repurchased under its share repurchase program).

     

     

     

     

    ITEM 1(a).NAME OF ISSUER:

     

    I-Mab

     

    ITEM 1(b).ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

     

    55th Floor, New Bund Center
    555 West Haiyang Road, Pudong District
    Shanghai, 200124
    People's Republic of China

     

    ITEM 2(a).NAME OF PERSON FILING:

     

    Jingwu Zhang Zang
    Mabcore Limited

     

    ITEM 2(b).ADDRESS OF PRINCIPAL BUSINESS OFFICE, OR, IF NONE, RESIDENCE:

     

    Jingwu Zhang Zang
    55th Floor, New Bund Center
    555 West Haiyang Road, Pudong District
    Shanghai, 200124

    People's Republic of China

     

    Mabcore Limited
    Trinity Chambers, P.O. Box 4301
    Road Town, Tortola, British Virgin Islands

     

    ITEM 2(c).CITIZENSHIP:

     

    Jingwu Zhang Zang – United States
    Mabcore Limited – British Virgin Islands

     

    ITEM 2(d).TITLE OF CLASS OF SECURITIES:

     

    Ordinary shares, par value of $0.0001 per share

     

    ITEM 2(e).CUSIP NO.:

     

    44975P 103

     

    There is no CUSIP number assigned to the ordinary shares of the Issuer. CUSIP number 44975P 103 has been assigned to the American Depositary Shares ("ADSs") of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "IMAB." Each 10 ADSs represents 23 ordinary shares.

     

    ITEM 3.IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13D-1(B), OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSONS FILING IS A:

     

    Not applicable

     

     

     

     

    ITEM 4.OWNERSHIP

     

    The following information with respect to the ownership of the ordinary shares of par value of $0.0001 per share of I-Mab by each of the reporting persons is provided as of December 31, 2023:

     

    Reporting Person  Amount
    beneficially
    owned:
      Percent of
    class:
      Sole power
    to
    vote or
    direct
    the vote:
      Shared
    power to
    vote or to
    direct the
    vote:
      Sole power
    to
    dispose or to
    direct the
    disposition
    of:
      Shared
    power
    to dispose or
    to direct the
    disposition
    of:
     
    Jingwu Zhang Zang  10,454,937  5.60  10,454,937  0  10,454,937  0 
    Mabcore Limited  2,072,899  1.12  2,072,899  0  2,072,899  0 

     

    The 10,454,937 ordinary shares of the Issuer beneficially owned by Dr. Jingwu Zhang Zang comprise (i) 2,072,899 ordinary shares directly held by Mabcore Limited as described below, (ii) 273,256 ordinary shares held by Dr. Zang through The 2019 Hasselt Revocable Trust, (iii) 5,962,625 ordinary shares, including 114,890 ordinary shares in the form of ADSs, held by Dr. Zang through The Doctor Zang 2020 Dynasty Trust, and (iv) 1,140,241 ordinary shares in the form of ADSs and 1,005,916 ordinary shares issuable upon exercise of options exercisable within 60 days after December 31, 2023 held by Dr. Zang. The 2019 Hasselt Revocable Trust was established under the laws of the State California and is co-managed by Dr. Zang and Ms. Zang, each as a settlor and a trustee. The Doctor Zang 2020 Dynasty Trust was established under the laws of the State of California and is co-managed by Dr. Zang, as the settlor and the investment trustee and by Ms. Zang, as the trustee.

     

    Mabcore Limited, a British Virgin Islands company, directly holds 2,072,899 ordinary shares of the Issuer. Dr. Zang, through himself and The Jingwu Zhang Zang 2018 Irrevocable Family Trust, owns a 55.6% equity interest in Mabcore Limited. Three other individuals own the remaining equity interest in Mabcore Limited. Dr. Zang is the sole director of Mabcore Limited. The Jingwu Zhang Zang 2018 Irrevocable Family Trust was established under the laws of New York and is co-managed by Ms. Zang, as the trustee and by Dr. Zang, as the settlor. Pursuant to the currently effective memorandum and articles of association of Mabcore Limited, Dr. Zang, as the sole director, has the power to direct the actions of Mabcore Limited, including the voting and disposal of Mabcore Limited's shares in I-Mab. Accordingly, Dr. Zang is deemed to indirectly own all of the 2,072,899 ordinary shares held by Mabcore Limited, while three other individuals are only entitled to their respective pro-rata economic interest in Mabcore Limited.

     

    The percentage of the class of securities beneficially owned by each of the reporting persons as of December 31, 2023 is based on 185,613,662 ordinary shares outstanding as of December 31, 2023 (excluding 660,200 ordinary shares issued to the depositary bank of I-Mab for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of I-Mab and 7,799,867 treasury shares in the form of ADSs that the Issuer repurchased under its share repurchase program).

     

    ITEM 5.OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    Not applicable

     

    ITEM 6.OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     

    Not applicable

     

    ITEM 7.IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON

     

    Not applicable

     

    ITEM 8.IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

     

    Not applicable

     

    ITEM 9.NOTICE OF DISSOLUTION OF GROUP

     

    Not applicable

     

    ITEM 10.CERTIFICATIONS

     

    Not applicable

     

     

     

     

    LIST OF EXHIBITS

     

    Exhibit No.

     

    Description

    99.1   Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to Schedule 13G/A filed on February 11, 2022 by the reporting persons with the Securities and Exchange Commission)

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 9, 2024

       
      Jingwu Zhang Zang
       
       /s/ Jingwu Zhang Zang
      Jingwu Zhang Zang
       
      Mabcore Limited
       
      By: /s/ Jingwu Zhang Zang
      Name: Jingwu Zhang Zang
      Title: Director

     

     

     

    Get the next $IMAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMAB

    DatePrice TargetRatingAnalyst
    12/9/2021$96.00Buy
    Siebert Williams Shank
    11/1/2021$83.00 → $85.00Buy
    Needham
    9/1/2021$75.00 → $95.00Buy
    HC Wainwright & Co.
    More analyst ratings